logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
Y

Yohann Loriot

gustave roussy

76H-index
1.1KPaper Count
5.4WCitation Count
Published Papers 302
Publication Date
logo
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling
errNature Medicine
IF50
err2026-06-25
err0
errOAAI
errDéborah Suissa; Marine Fidelle; Ella Reich; Thao-Nguyen Pham; Simon Thomas; Johannes R. Björk; Peng Liu; Liwei Zhao; Koji Kitaoka; Eléonore Piard; Isabelle Lebhar; Ai-Ling Tian; Cassandra Thelemaque; Carolina Alves Costa Silva; Eric Deutsch; Yohann Loriot; Nicola Segata; Gianmarco Piccinno; Geke A. P. Hospers; Saman Maleki Vareki; Michael S. Silverman; John G. Lenehan; Véronique Bataille; David Boulate; Tatiana Kuznetsova; Rinse K. Weersma; Meriem Messaoudene; Sylvère Durand; Carlijn M. van der Aalst; Harry J. de Koning; Beatrice Schuler-Thurner; I. Jolanda M. de Vries; Edmond Rafie; Renée Maria Saliby; Marc Machaalani; Sebastian Haferkamp; Bastian Schilling; Serena Porcari; Chiara Ciccarese; Roberto Iacovelli; Chiara Cremolini; Toni K. Choueiri; Arielle Elkrief; Guido Kroemer; Lucie Heinzerling; Kenji Chamoto; Gianluca Ianiro; Bertrand Routy; Lisa Derosa; Nikos Paragios; Laurence Zitvogel
errShare
errSave
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma
errFuture Oncology
IF2.6
err2026-05-16
err0
PREAI
errMatthew D. Galsky; Alexandra Drakaki; Arnab Basu; Bradley McGregor; Jens Bedke; Yohann Loriot; Eiji Kikuchi; Jun Guo; Benjamin Garmezy; Srikala S. Sridhar; Parminder Singh; Vadim S. Koshkin; Mark Fleming; Gunnar Klauss; Daisy Lin; Chelsea Liu; Andrea B. Apolo; Thomas Powles
errShare
errSave
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations
errNature Genetics
IF29
err2025-12-08
err0
errOAAI
errCarla Tangermann; Avantika Ghosh; Martin Ziegler; Francesco Facchinetti; Jannis Stappenbeck; Yagmur Oyku Carus Sahin; Marisa Riester; Luise Carmina Viardot; Tobias Zundel; Luc Friboulet; Antoine Hollebecque; José J. Naveja; Angela Wanninger; Maria Elena Hess; Tilman Brummer; Melanie Boerries; Sonja Loges; Yohann Loriot; Anna L. Illert; Sven Diederichs
errShare
errSave
A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases
errFUTURE ONCOLOGY
IF2.6
err2025-11-01
err0
PREAI
errTombal, Bertrand; Saad, Fred; Gallardo, Enrique; Soares, Andrey; Loriot, Yohann; McDermott, Ray; Briers, Erik; Lagstrom, Mikael; Coens, Corneel; Poncet, Coralie; Fournier, Beatrice; Gillessen, Silke
errShare
errSave
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract
errFUTURE ONCOLOGY
IF2.6
err2025-11-01
err1
PREAI
errPowles, Thomas; Tagawa, Scott T.; Vulsteke, Christof; Gross-Goupil, Marine; Park, Se Hoon; Necchi, Andrea; De Santis, Maria; Duran, Ignacio; Morales-Barrera, Rafael; Guo, Jun; Sternberg, Cora N.; Bellmunt, Joaquim; Goebell, Peter J.; Kovalenko, Maria; Boateng, Freda; Sierecki, Mitch; Wang, Lu; Sima, Camelia S.; Waldes, Jana; Bangs, Rick; Loriot, Yohann; Grivas, Petros
errShare
errSave
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
errAnnals of Oncology
IF65.4
err2025-10-17
err0
errOAAI
errT. Powles; S.A. Hussain; M.A. Climent; I.G. Carbonero; J. Molina-Cerrillo; J. Puente; P. Borrega; J. Malik; L-M Dourthe; R. Jones; D. Castellano; I. Durán; Y. Loriot; G. Priyadarshini; B. Szabados; F. Jamal; Y.Q. Wang; N. Kotriwala; F. Jackson-Spence; C. Ackerman; E. Grande
errShare
errSave
The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond
errTherapeutic Advances in Medical Oncology
IF4.2
err2025-09-29
err0
errOAAI
errAlice Bernard-Tessier; Natacha Naoun; Solenn Barraud; Ronan Flippot; Cedric Pobel; Macarena Rey; Capucine Baldini; Christophe Massard; Anna Patrikidou; Alina Fuerea; Mario Di Palma; Laurence Albigès; Yohann Loriot; Karim Fizazi
errShare
errSave
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy
errFUTURE ONCOLOGY
IF2.6
err2025-09-01
err0
errOAAI
errGrivas, Petros; Tagawa, Gurdeep; Jain, Rohit K.; Bupathi, Manojkumar; Balar, Arjun; Rezazadeh Kalebasty, Arash; George, Saby; Palmbos, Phillip; Nordquist, Luke; Petrylak, Daniel P.; Davis, Nancy; Sternberg, Cora N.; Agarwal, Neeraj; Park, Chandler; Tonelli, Julia; Zhou, Huafeng; Bangs, Rick; Loriot, Yohann
errShare
errSave
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma
errFuture Oncology
IF2.6
err2025-07-29
err0
errOAAI
errThomas B. Powles; Enrique Grande; Nimira Alimohamed; Niara Oliveira; Srikala S. Sridhar; Alexandra Drakaki; Ravindran Kanesvaran; Yohann Loriot; Andrea Necchi; Sonia Franco; Dingfeng Jiang; Kristel Apolinario; Wei Zhang; Matthew D. Galsky
errShare
errSave
The next-generation of nectin-4 targeted therapies
errAnnals of Oncology
IF65.4
err2025-07-14
err0
PREAI
errC. Pobel; Y. Loriot
errShare
errSave
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer
errDiagnostic and Interventional Imaging
IF8.1
err2025-06-08
err0
PREAI
errGhina Jardali; Littisha Lawrance; Lama Dawi; Jules Dupont; Othilie Gautier; Michèle Kind; Samy Ammari; Joya Hadchiti; Aurélie Choucair; Arnaud Bayle; Paul-Henry Cournède; Isabelle Borget; Serge Muller; François Bidault; Corinne Balleyguier; Antoine Hollebecque; Yohann Loriot; Filippo Gustavo Dall-Olio; Benjamin Besse; Ludovic Lacroix; Etienne Rouleau; Alexandre Bône; Fabrice André; Christophe Massard; Fabrice Barlesi; Antoine Italiano; Nathalie Lassau
errShare
errSave
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease
errEuropean Urology
IF25.2
err2025-06-03
err0
errOAAI
errJoaquim Bellmunt; Thomas Powles; Se Hoon Park; Eric Voog; Begona P. Valderrama; Howard Gurney; Anders Ullén; Yohann Loriot; Srikala S. Sridhar; Norihiko Tsuchiya; Cora N. Sternberg; Jeanny B. Aragon-Ching; Daniel P. Petrylak; Miguel A. Climent Duran; Karin Tyroller; Jason Hoffman; Natalia Jacob; Petros Grivas; Shilpa Gupta
errShare
errSave
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project
errEuropean Urology Oncology
IF9.3
err2025-06-01
err0
PREAI
errAlexandra Masson-Lecomte; Guillaume Grisay; Julien Van Damme; Verane Achard; Laura S. Mertens; Thierry N. Boellaard; David D’Haese; Beatrice Fournier; Anne-Sophie Govaerts; Robert Huddart; Francesco Soria; Lars Dyrskjøt; Yves Allory; Martina Pecoraro; Saskia Litiere; Bertrand Tombal; Valeria Panebianco; Yohann Loriot
errShare
errSave
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
errAnnals of Oncology
IF65.4
err2025-05-30
err0
errOAAI
errB. Tombal; A. Choudhury; F. Saad; E. Gallardo; A. Soares; Y. Loriot; R. McDermott; A. Rodriguez-Vida; P. Isaacsson Velho; F. Nolè; F. Cruz; T. Roumeguere; G. Daugaard; R. Yamamura; E. Bompas; P. Maroto; F. Gomez Veiga; I. Skoneczna; K. Martins da Trindade; F. Mavignier Carcano; F. Lecouvet; C. Coens; C. Poncet; B. Fournier; S. Gillessen
errShare
errSave
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
errlancet oncology
IF0
err2025-05-28
err0
PREAI
errShilpa Gupta; Yohann Loriot; Michiel S Van der Heijden; Jens Bedke; Begoña P Valderrama; Eiji Kikuchi; Aude Fléchon; Daniel Petrylak; Maria De Santis; Matthew D Galsky; Jae Lyun Lee; Umang Swami; Srikala S Sridhar; Ugo De Giorgi; Phoebe Wright; Vanessa Shih; Yi-Tsung Lu; Xuesong Guan; Ryan Dillon; Aditya Shetty; Blanca Homet Moreno; Jennifer L Beaumont; Intan Purnajo; Shauna McManus; Thomas Powles
errShare
errSave
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial
errEuropean Urology Oncology
IF9.3
err2025-05-02
err0
errOAAI
errPetros Grivas; Jeanny B. Aragon-Ching; Joaquim Bellmunt; Yohann Loriot; Miguel A. Climent Duran; Srikala S. Sridhar; Po-Jung Su; Se Hoon Park; Evgeny Kopyltsov; Yoshiaki Yamamoto; Natalia Jacob; Jason Hoffman; Karin Tyroller; Juliane Manitz; Mairead Kearney; Michael Schlichting; Thomas Powles
errShare
errSave
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60
errEuropean Urology Oncology
IF9.3
err2025-02-01
err0
PREAI
errBertrand Tombal; Yohann Loriot
errShare
errSave
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
errANNALS OF ONCOLOGY
IF65.4
err2025-02-01
err4
PREAI
errPowles, T.; Tagawa, S.; Vulsteke, C.; Gross-Goupil, M.; Park, S. H.; Necchi, A.; De Santis, M.; Duran, I.; Morales-Barrera, R.; Guo, J.; Sternberg, C. N.; Bellmunt, J.; Goebell, P. J.; Kovalenko, M.; Boateng, F.; Sierecki, M.; Wang, L.; Sima, C. S.; Waldes, J.; Loriot, Y.; Grivas, P.
errShare
errSave
Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study
errFUTURE ONCOLOGY
IF2.6
err2025-01-15
err0
errOAAI
errPowles, Thomas; Park, Se Hoon; Gurney, Howard; Loriot, Yohann; Sridhar, Srikala S.; Bellmunt, Joaquim; di Pietro, Alessandra; Grivas, Petros
errShare
errSave
Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?
errINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
IF6.5
err2024-12-01
err0
PREAI
errMavrikios, Antoine; Baldini, Capucine; Loriot, Yohann; Henon, Clemence; Marabelle, Aurelien; Postel-Vinay, Sophie; Champiat, Stephane; Danlos, Francois-Xavier; Quevrin, Clement; Lopes, Eloise; Gazzah, Anas; Bahleda, Rastislav; Massard, Christophe; Deutsch, Eric; Levy, Antonin
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
L
Laurence Zitvogel
H-index: 165 · Papers: 1.2K
J
Johann S. de Bono
H-index: 160 · Papers: 2.5K
C
Carlos Caldas
H-index: 158 · Papers: 1.4K
T
Toni K. Choueiri
H-index: 149 · Papers: 2.4K
F
Fabrice André
H-index: 148 · Papers: 1.8K
View more